DE68914644D1 - Verringerung der nebeneffekte bei der krebstherapie. - Google Patents

Verringerung der nebeneffekte bei der krebstherapie.

Info

Publication number
DE68914644D1
DE68914644D1 DE68914644T DE68914644T DE68914644D1 DE 68914644 D1 DE68914644 D1 DE 68914644D1 DE 68914644 T DE68914644 T DE 68914644T DE 68914644 T DE68914644 T DE 68914644T DE 68914644 D1 DE68914644 D1 DE 68914644D1
Authority
DE
Germany
Prior art keywords
side effects
cancer therapy
reducing side
administration
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68914644T
Other languages
English (en)
Other versions
DE68914644T2 (de
Inventor
Joseph Cummins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amarillo Cell Culture Co Inc
Original Assignee
Amarillo Cell Culture Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amarillo Cell Culture Co Inc filed Critical Amarillo Cell Culture Co Inc
Publication of DE68914644D1 publication Critical patent/DE68914644D1/de
Application granted granted Critical
Publication of DE68914644T2 publication Critical patent/DE68914644T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE68914644T 1988-01-06 1989-01-03 Verringerung der nebeneffekte bei der krebstherapie. Expired - Fee Related DE68914644T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/141,621 US5017371A (en) 1988-01-06 1988-01-06 Method for reducing side effects of cancer therapy
PCT/US1989/000024 WO1989006139A1 (en) 1988-01-06 1989-01-03 Reduction of side effects of cancer therapy

Publications (2)

Publication Number Publication Date
DE68914644D1 true DE68914644D1 (de) 1994-05-19
DE68914644T2 DE68914644T2 (de) 1994-07-21

Family

ID=22496471

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68914644T Expired - Fee Related DE68914644T2 (de) 1988-01-06 1989-01-03 Verringerung der nebeneffekte bei der krebstherapie.

Country Status (11)

Country Link
US (1) US5017371A (de)
EP (1) EP0396616B1 (de)
JP (1) JP2813017B2 (de)
AT (1) ATE104152T1 (de)
AU (1) AU630598B2 (de)
CA (1) CA1336398C (de)
DE (1) DE68914644T2 (de)
DK (1) DK160690A (de)
HK (1) HK24595A (de)
HU (1) HU206987B (de)
WO (1) WO1989006139A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102870A (en) * 1989-04-14 1992-04-07 Schering Ag Treatment and prevention of oral mucositis with growth factors
IE62496B1 (en) * 1990-04-19 1995-02-08 Res Dev Foundation Antibody conjugates for treatment of neoplastic disease
US5824297A (en) * 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
US5215741A (en) * 1990-10-30 1993-06-01 Amarillo Cell Culture Company, Incorporated Method for prevention of parasite infections
US5486509A (en) * 1991-06-28 1996-01-23 University Of Miami Method of preventing and treating chemotherapy-induced alopecia
US5817625A (en) * 1992-09-21 1998-10-06 Oncogene Science, Inc. Methods of prevention of oral mucositis with transforming growth factor beta
US7294332B2 (en) 1995-10-04 2007-11-13 Schering Corporation Combination therapy (temozolomide and α-IFN) for advanced cancer
WO1997012630A1 (en) * 1995-10-04 1997-04-10 Schering Corporation Combination of temozolomide and alpha-ifn for the treatment of advanced cancer
US20030108519A1 (en) * 1996-05-09 2003-06-12 Pharma Pacific Pty Ltd. Therapeutic applications of high dose in terferon
BR9709068A (pt) 1996-05-09 2000-01-11 Pharma Pacific Pty Ltd Processo de tratamento.
CN1151840C (zh) * 1996-05-09 2004-06-02 太平洋制药控股公司 干扰素在制备用于治疗哺乳动物肿瘤病的药剂中的应用
WO1998035659A1 (en) * 1997-02-18 1998-08-20 Lxr Biotechnology Inc. Bak promotor expression system
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
AU783208B2 (en) * 1999-12-09 2005-10-06 Novartis Vaccines And Diagnostics, Inc. Method for administering a cytokine to the central nervous system and the lymphatic system
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
DK1414471T3 (da) 2001-07-17 2012-07-16 Res Dev Foundation Terapeutiske midler omfattende pro-apoptotiske proteiner
AU2003275985A1 (en) * 2002-06-12 2003-12-31 Research Development Foundation Immunotoxin as a therapeutic agent and uses thereof
WO2004000266A1 (en) * 2002-06-20 2003-12-31 Yuriy Vasilievich Tyagotin Method for oral transmucosal delivery of interferon
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
AU2006210769A1 (en) * 2005-02-01 2006-08-10 Research Development Foundation BLyS fusion proteins for targeting BLyS receptor and methods for treatment of B-cell proliferative disorders
US8557863B2 (en) * 2005-09-27 2013-10-15 Robert Benson Aylor Suppression and prevention of tumors
AU2007205545B9 (en) * 2006-01-12 2012-10-18 Hokusan Co. Ltd. Oral composition containing interferon-alpha
US20090203661A1 (en) * 2006-10-12 2009-08-13 Safe Stephen H Betulinic acid, derivatives and analogs thereof and uses therefor
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
SG10201404883YA (en) 2009-08-14 2014-10-30 Berg Llc Vitamin d3 and analogs thereof for treating alopecia
US9642893B2 (en) 2013-07-03 2017-05-09 Joseph Cummins Method for reducing injury and stabilizing muscle using orally administered interferon
EP3900786A1 (de) 2015-10-29 2021-10-27 CLS Therapeutics Limited Verwendung von dnase zur verbesserung der wirksamkeit und sicherheitsprofil der strahlentherapie oder chemotherapie gegen krebs.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
ZA754725B (en) * 1974-08-01 1976-06-30 H Stickl Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
US3972995A (en) * 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
DK485977A (da) * 1977-11-01 1979-05-02 Ess Foodeksport Fremgangsmaade til udvinding af et biologisk aktivt materiale fra svineblodfraktioner
GB2016015B (en) * 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4460574A (en) * 1980-06-16 1984-07-17 Yabrov Alexander A Prophylaxis or treatment of interferon-sensitive diseases
US4462985A (en) * 1980-08-22 1984-07-31 University Of Illinois Foundation Delivery of biologically active components of heterologous species interferon isolates
JPS57501236A (de) * 1980-08-22 1982-07-15
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4497795A (en) * 1982-12-13 1985-02-05 The Texas A&M University System Method of regulating appetite and efficiency of food utilization employing interferon
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4649075A (en) * 1984-08-09 1987-03-10 Leonora Jost Transdermal and transmucosal vortexed foam devices and the method of making
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
EP0177342A3 (de) * 1984-10-04 1987-12-02 Genentech, Inc. Orale Formulierungen therapeutischer Proteine
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease

Also Published As

Publication number Publication date
US5017371A (en) 1991-05-21
EP0396616A1 (de) 1990-11-14
DK160690D0 (da) 1990-07-03
DK160690A (da) 1990-07-03
JP2813017B2 (ja) 1998-10-22
EP0396616A4 (en) 1991-10-16
AU630598B2 (en) 1992-11-05
AU2941489A (en) 1989-08-01
HUT56720A (en) 1991-10-28
ATE104152T1 (de) 1994-04-15
HU206987B (en) 1993-03-01
HK24595A (en) 1995-03-03
EP0396616B1 (de) 1994-04-13
JPH03504375A (ja) 1991-09-26
DE68914644T2 (de) 1994-07-21
CA1336398C (en) 1995-07-25
WO1989006139A1 (en) 1989-07-13
HU890950D0 (en) 1991-08-28

Similar Documents

Publication Publication Date Title
DE68914644D1 (de) Verringerung der nebeneffekte bei der krebstherapie.
FI884013A (fi) Konjugat av cytokiner med immunoglobuliner.
NO306377B1 (no) Doseform for avgivelse av et medikament
GR3017891T3 (en) Dosage form for delivering drug in short-time period.
ATE96308T1 (de) Dosierform fuer verabreichung in der humanmedizin.
DK360188D0 (da) Laegemiddelafgivelsesorgan
GR1000419B (el) Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου.
NZ504928A (en) Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
NO892764D0 (no) Medikamentell administreringsform for droevtyggere.
TW263437B (de)
EP0280593A3 (en) Composition on the basis of an amino-acid and vitamins for use in cancer therapy
MX9701478A (es) Uso de il-4 para aumentar la potencia de agentes quimioterapeuticos.
ZA918336B (en) Udpg as a rescue agent in cancer therapy after the administration of antipyrimidine or related anti-tumor agents with or without bau
DK0427633T3 (da) Anvendelse af et polypeptid med gammainterferonaktivitet til fremstilling af farmaceutiske præparater beregnet til behandling af primitiv pleuracancer
DK650888A (da) Farmaceutisk praeparat med virkning mod cancer
BR7100749U (pt) Adaptador para isqueiro com finalidade estetica e medicinal
ATE99959T1 (de) Immunokonjugate fuer krebs-diagnose und -therapie.
ES1008162Y (es) Chupete con efectos terapeuticos:

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Free format text: PATENTANWAELTE REICHEL UND REICHEL, 60322 FRANKFURT

8339 Ceased/non-payment of the annual fee